CertaPeptides (CERTALAB S.R.L.) is a reseller, not a manufacturer, and makes no medical, therapeutic, or efficacy claims
In the New England Journal of Medicine, Garvey and colleagues [5] report the results of the REDEFINE 1 trial, a 68-week, phase 3a double-blind, placebo-controlled and active-controlled trial evaluating the efficacy and safety of coadministered cagrilintide and semaglutide in adults with obesity [body mass index (BMI) 30 kg/m 2 ] or overweight (BMI 27 kg/m 2 ) with at least one weight-related comorbidity
For those unfamiliar with why this happens, the discomfort can feel alarming and lead to premature discontinuation of an otherwise well-designed protocol
Dietary Considerations
If any side effect persists or worsens, contact your prescriber promptly
It is often the missing piece for people who want visible changes, not just lower numbers